Ark BioPharmaceutical Receives Approval for Azstarys in China for ADHD Treatment

Ark Biopharmaceutical, now known as Ark BioPharmaceutical, has received approval from China’s NMPA for their drug Azstarys to treat ADHD in patients 6 years and older. Azstarys, a central nervous system stimulant, contains serdexmethylphenidate (SDX) and immediate-release dexmethylphenidate (d-MPH) in a fixed ratio to control ADHD symptoms effectively. ADHD is a common disorder in China, affecting over 23 million individuals, with limited treatment options currently available. In clinical trials, Azstarys met primary and key secondary endpoints, showing significant improvements in ADHD symptoms compared to a placebo. This approval marks a significant development in ADHD treatment options in China, providing patients…